• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pharmacogenomics and Personalized Medicine >Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder
【24h】

Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder

机译：CYP2D6基因多态性对氟伏沙明在抑郁症和合并症患者中的疗效和安全性的影响

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Fluvoxamine therapy is used for treatment of patients with depressive disorder, but it is often ineffective, and some patients suffer from dose-dependent undesirable side effects such as vertigo, headache, indigestion, xerostomia, increased anxiety, etc. CYP2D6 is involved in the biotransformation of fluvoxamine. Meanwhile, the genes encoding these isoenzymes have a high level of polymorphism, which may affect the protein synthesis. Objective: The primary objective of our study was to investigate the effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder, in order to develop the algorithms of optimization of fluvoxamine therapy for reducing the risk of dose-dependent undesirable side effects and pharmacoresistance. Methods: The study involved 45 male patients (average age: 36.44±9.96 years) with depressive disorder and comorbid alcohol use disorder. A series of psychometric scales was used in the research. Genotyping of CYP2D6 (1846G>A) was performed using real-time polymerase chain reaction. Results: According to results of Mann–Whitney U -test, statistically significant differences between the efficacy and safety of fluvoxamine were obtained on 9th and 16th days of therapy in patients with GG and GA genotypes (The Hamilton Rating Scale for Depression: 10.0 [10.0; 23.0] vs 25.0 [24.0; 16.0] ( P A polymorphic marker.
机译：背景：氟伏沙明疗法用于治疗抑郁症患者，但通常无效，并且一些患者患有剂量依赖性不良副作用，如眩晕，头痛，消化不良，口腔干燥，焦虑增加等。CYP2D6参与其中氟伏沙明的生物转化。同时，编码这些同工酶的基因具有高水平的多态性，这可能影响蛋白质的合成。目的：本研究的主要目的是研究CYP2D6基因多态性对氟伏沙明在抑郁症和合并症患者中的疗效和安全性的影响，以开发优化氟伏沙明治疗以降低风险的算法剂量依赖性不良副作用和药物抗药性。方法：本研究纳入了45例患有抑郁症和合并酒精滥用症的男性患者（平均年龄：36.44±9.96岁）。该研究使用了一系列心理量表。 CYP2D6（1846G> A）的基因分型使用实时聚合酶链反应进行。结果：根据Mann-Whitney U检验的结果，在患有GG和GA基因型的患者中，在治疗的第9天和第16天，氟伏沙明的疗效和安全性在统计学上有显着差异（汉密尔顿抑郁量表：10.0 [10.0 ; 23.0] vs 25.0 [24.0; 16.0]（PA多态性标记。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号